47 completed, 7 terminated, 3 active not recruiting, 3 recruiting. 25 Phase 2, 24 Phase 1, 18 Phase 3.
By phase and status
Phase Trials Status Phase 2 25 Completed 18 , Terminated 4 , Recruiting 2 , Withdrawn 1 Phase 1 24 Completed 19 , Terminated 2 , Active not recruiting 1 , Recruiting 1 , Unknown 1 Phase 3 18 Completed 11 , Active not recruiting 2 , Not yet recruiting 1 , Recruiting 1 , Terminated 1 , Unknown 1 , Withdrawn 1
Follow R-Pharm: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever RPH-104 - Familial Mediterranean Fever, FMF Phase 3 Not yet recruiting 18 2026-12-01 2026-10-19 A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI RPH-030, Vectibix®, Irinotecan - Metastatic Colorectal Cancer Phase 1 Recruiting 180 2025-04-17 2026-04-22 A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations RPH-035, Ocrevus® - Multiple Sclerosis Phase 1 Active not recruiting 180 2025-04-16 2026-07-14 A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer RPH-051, Docetaxel, Perjeta® - Locally Advanced Breast Cancer, Metastatic Breast Cancer Phase 3 Active not recruiting 246 2024-08-09 2026-07-14 A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma RPH-002, Erbitux®, Cisplatin - Head and Neck Squamous Cell Carcinoma Phase 3 Completed 161 2024-08-08 2026-07-14 Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma RPH-075, Keytruda® - Skin Melanoma Phase 3 Completed 266 2023-09-27 2026-07-15 Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL), SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL - Lung Diseases, Interstitial Phase 2 / Phase 3 Recruiting 138 2023-08-23 2024-11-19 Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis OKZ q4w - Juvenile Idiopathic Arthritis Phase 2 Recruiting 71 2023-03-17 2026-04-08 Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms RPH-075, Keytruda® - Skin Melanoma, Squamous Non-small-cell Lung Cancer Phase 1 Completed 90 2023-03-01 2026-07-15 Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and Flutter Refralon - Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation Completed 1147 2022-11-11 2023-10-12 Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19 AZD1222, rAd26-S - COVID-19 Phase 1 / Phase 2 Completed 100 2021-09-15 2022-06-03 Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection Olokizumab, Standard therapy - COVID-19 Completed 3087 2021-07-14 2023-01-20 Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19) AZD1222, rAd26-S - COVID-19 Phase 1 / Phase 2 Completed 100 2021-07-13 2022-10-26 Study of Efficacy of Different Treatment Regimens of Olokizumab Olokizumab, Standard therapy - COVID-19 Phase 3 Unknown 198 2021-07-08 2023-02-13 Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention AZD1222, rAd26-S - COVID-19 Phase 2 Completed 100 2021-03-05 2022-06-03 Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis RPH-104 - Idiopathic Recurrent Pericarditis Phase 3 Active not recruiting 17 2020-12-11 2024-11-15 Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction RPH-104 80 mg, Placebo - Acute ST Segment Elevation Myocardial Infarction Phase 2 Completed 102 2020-12-07 2024-06-24 Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). Olokizumab 64 mg, Placebo - COVID-19 Phase 2 / Phase 3 Withdrawn 2020-06-30 2021-11-08 A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma RPH-002, Erbitux®, cisplatin - Head and Neck Squamous Cell Carcinoma Phase 1 Completed 118 2020-06-15 2026-07-14 Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19 Favipiravir, Standard of care (SOC), standard concomitant therapy - COVID-19 Phase 3 Completed 168 2020-05-20 2023-01-20
Showing 20 of 64. Sign in to see all of them.
Conditions studied Breast Neoplasms (15) · Neoplasms (8) · COVID-19 (7) · Carcinoma, Non-Small-Cell Lung (4) · Coronavirus Infections (4) · Lung Diseases (4) · Respiration Disorders (4) · Hepatitis C (3) · Squamous Cell Carcinoma of Head and Neck (3) · Arthritis, Rheumatoid (2) · Bronchiolitis Obliterans Syndrome (2) · Lung Neoplasms (2) · Melanoma (2) · Neoplasm Metastasis (2) · Alcoholism (1)
Interventions ixabepilone (28) · Capecitabine (7) · Docetaxel (5) · Epothilones (5) · Ritonavir (5) · narlaprevir (5) · olokizumab (5) · Cetuximab (4) · ChAdOx1 nCoV-19 (3) · Cisplatin (3) · Paclitaxel (3) · Standard of Care (3) · BMS 181339 (2) · Bevacizumab (2) · Carboplatin (2)
Countries Russia (32) · United States (22) · Italy (10) · France (9) · Spain (7) · Argentina (5) · Greece (5) · Japan (5) · South Korea (5) · Taiwan (5) · United Kingdom (5) · Australia (4) · Belgium (4) · Canada (4) · Germany (4)
Top investigators Mikhail Samsonov (29) · David R. Spriggs, MD (1) · Linnea Chap, MD (1) · Mark Genovese, Dr (1) · Sibel Goksel, MD, PhD (1) · Tsutomu Takeuchi, Professor (1) · Yan Lavrovsky (1)
Results publications PMID 21128114 , PMID 21937232 , PMID 24472478 , PMID 17261851 , PMID 17968020 , PMID 23589560 , PMID 25925990 , PMID 27645244 , PMID 29522361 , PMID 33902621 , PMID 39133774
NIH funding 2008 (2)